La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish proprietary reports and prepare custom reports.
Folate Receptor alpha: a clinically validated target for ovarian cancer with commercial potential and a decent competitive environment
STUTTGART, Germany I August 05, 2025 I La Merie Publishing released its newest product entitled: Folate Receptor alpha (FRα) Targeted Therapy: a Competitor Analysis
Folate receptor alpha (FRα) is a cell surface GPI-anchored protein overexpressed in several solid tumors with highest prevalence in ovarian cancer and lung adenocarcinoma but restricted expression in normal tissues. An antibody drug conjugate (ADC) with a microtubule inhibitor (MTI) payload recently received accelerated approval from the FDA for FRα-expressing platinum-resistant ovarian cancer. Thus, folate receptor alpha is a clinically validated target with commercial potential as evidenced by sales of more than US$ 500 mln in its second full year of commercialization after first approval in 2022. Furthermore, the FRα-targeted ADC was the main reason for an equity value of US$ 10 bln when the originator company Immunogen was acquired by Abbvie.
Folate receptor alpha holds great promise as a target for next generation improved drug candidates based on drug modalities known to enhance effector function and/or to broaden the therapeutic window. Among FRα-targeted drug modalities in use for next generation therapy candidates are ADCs with novel targeting moieties and linker/payload technologies as well as novel small molecule drug conjugates. Furthermore, next generation cell therapy modalities and radiopharmaceuticals are advancing in the pipeline. And T-cell or NK cell engaging bispecific antibodies are further drug modalities applied to folate receptor alpha therapies.
This product consists of a competitor description and analysis in a tabular format provided as a pdf document which is sent by e-mail within one day, usually within one hour. The pdf report includes a compilation of marketed and currently active projects in research and development of FRα-targeted product and product candidates.
The report “Folate Receptor alpha (FRα) Targeted Therapy: a Competitor Analysis” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/folate-receptor-alpha-fr%ce%b1-targeted-therapy-a-competitor-analysis/
